Real-World Insights on Tildrakizumab for Plaque Psoriasis: A Meta-Analysis of Four Observational Studies - Top-Institutions - MDSpire

Real-World Insights on Tildrakizumab for Plaque Psoriasis: A Meta-Analysis of Four Observational Studies

  • By

  • Athanasios Tsianakas

  • Nina Magnolo

  • Afra Kempf

  • Frank Andersohn

  • Astrid Kirsch

  • Georgios Kokolakis

  • Dennis Niebel

  • March 28, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Rheumatology
    • Clinical Trials

  • #3

    Massachusetts General Hospital (MGH)
    Massachusetts General Hospital (MGH)

    Boston, MA

    Key Differentiators

    • Dermatology
    • Immunology
    • Translational Research

  • #4

    Charité – Universitätsmedizin Berlin
    Charité – Universitätsmedizin Berlin

    Berlin, Berlin

    Key Differentiators

    • Dermatology
    • Clinical Immunology
    • Epidemiology

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Dermatology
    • Clinical Research
    • Immunodermatology

Original Source(s)

Real-World Insights on Tildrakizumab for Plaque Psoriasis: A Meta-Analysis of Four Observational Studies

  • by Athanasios Tsianakas, Nina Magnolo, Afra Kempf, Frank Andersohn, Astrid Kirsch, Georgios Kokolakis, Dennis Niebel

  • March 28, 2026

Related Content

Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse

Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.